The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease

Haematopoietic insufficiency is the treatment target of lower-risk myelodysplastic syndrome (MDS). Although erythropoiesis-stimulating agents (ESAs) are generally effective for treating anaemia, resistance can develop. Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) improves renal anaemia by pr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ryujiro Hara, Naoki Goto, Daisuke Furuya, Toshihiko Kitahara, Hiroki Numata, Shigeki Watanabe, Hiroshi Kawada, Kiyoshi Ando
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	myelodysplastic syndrome hypoxia-inducible factor-prolyl hydroxylase inhibitor roxadustat renal anaemia essential thrombocythemia Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c6b12a789d3d40dba5e269a5ed0a3177
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c6b12a789d3d40dba5e269a5ed0a3177
record_format	dspace
spelling	oai:doaj.org-article:c6b12a789d3d40dba5e269a5ed0a31772021-12-02T12:40:23ZThe Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease1662-657510.1159/000519568https://doaj.org/article/c6b12a789d3d40dba5e269a5ed0a31772021-11-01T00:00:00Zhttps://www.karger.com/Article/FullText/519568https://doaj.org/toc/1662-6575Haematopoietic insufficiency is the treatment target of lower-risk myelodysplastic syndrome (MDS). Although erythropoiesis-stimulating agents (ESAs) are generally effective for treating anaemia, resistance can develop. Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) improves renal anaemia by promoting endogenous erythropoietin production and normalizing iron metabolism. HIF-PH inhibitors could be used to treat MDS, but their efficacy and safety have not been studied. A 78-year-old female patient with essential thrombocythemia gradually developed anaemia and was diagnosed with therapy-related MDS 4 years later. The anaemia temporarily improved with ESAs, but the patient became transfusion dependent. At the same time, anaemia and chronic renal failure due to nephrosclerosis progressed, and the patient was diagnosed with MDS with renal anaemia. After switching from ESAs to roxadustat, an HIF-PH inhibitor, anaemia improved, and the patient was no longer transfusion dependent. No progression of the underlying disease or any adverse events was observed 4 months after initiating roxadustat.Ryujiro HaraNaoki GotoDaisuke FuruyaToshihiko KitaharaHiroki NumataShigeki WatanabeHiroshi KawadaKiyoshi AndoKarger Publishersarticlemyelodysplastic syndromehypoxia-inducible factor-prolyl hydroxylase inhibitorroxadustatrenal anaemiaessential thrombocythemiaNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCase Reports in Oncology, Vol 14, Iss 3, Pp 1574-1579 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	myelodysplastic syndrome hypoxia-inducible factor-prolyl hydroxylase inhibitor roxadustat renal anaemia essential thrombocythemia Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	myelodysplastic syndrome hypoxia-inducible factor-prolyl hydroxylase inhibitor roxadustat renal anaemia essential thrombocythemia Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ryujiro Hara Naoki Goto Daisuke Furuya Toshihiko Kitahara Hiroki Numata Shigeki Watanabe Hiroshi Kawada Kiyoshi Ando The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease
description	Haematopoietic insufficiency is the treatment target of lower-risk myelodysplastic syndrome (MDS). Although erythropoiesis-stimulating agents (ESAs) are generally effective for treating anaemia, resistance can develop. Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) improves renal anaemia by promoting endogenous erythropoietin production and normalizing iron metabolism. HIF-PH inhibitors could be used to treat MDS, but their efficacy and safety have not been studied. A 78-year-old female patient with essential thrombocythemia gradually developed anaemia and was diagnosed with therapy-related MDS 4 years later. The anaemia temporarily improved with ESAs, but the patient became transfusion dependent. At the same time, anaemia and chronic renal failure due to nephrosclerosis progressed, and the patient was diagnosed with MDS with renal anaemia. After switching from ESAs to roxadustat, an HIF-PH inhibitor, anaemia improved, and the patient was no longer transfusion dependent. No progression of the underlying disease or any adverse events was observed 4 months after initiating roxadustat.
format	article
author	Ryujiro Hara Naoki Goto Daisuke Furuya Toshihiko Kitahara Hiroki Numata Shigeki Watanabe Hiroshi Kawada Kiyoshi Ando
author_facet	Ryujiro Hara Naoki Goto Daisuke Furuya Toshihiko Kitahara Hiroki Numata Shigeki Watanabe Hiroshi Kawada Kiyoshi Ando
author_sort	Ryujiro Hara
title	The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease
title_short	The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease
title_full	The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease
title_fullStr	The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease
title_full_unstemmed	The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease
title_sort	effect of roxadustat on transfusion-dependent myelodysplastic syndrome complicated by chronic kidney disease
publisher	Karger Publishers
publishDate	2021
url	https://doaj.org/article/c6b12a789d3d40dba5e269a5ed0a3177
work_keys_str_mv	AT ryujirohara theeffectofroxadustatontransfusiondependentmyelodysplasticsyndromecomplicatedbychronickidneydisease AT naokigoto theeffectofroxadustatontransfusiondependentmyelodysplasticsyndromecomplicatedbychronickidneydisease AT daisukefuruya theeffectofroxadustatontransfusiondependentmyelodysplasticsyndromecomplicatedbychronickidneydisease AT toshihikokitahara theeffectofroxadustatontransfusiondependentmyelodysplasticsyndromecomplicatedbychronickidneydisease AT hirokinumata theeffectofroxadustatontransfusiondependentmyelodysplasticsyndromecomplicatedbychronickidneydisease AT shigekiwatanabe theeffectofroxadustatontransfusiondependentmyelodysplasticsyndromecomplicatedbychronickidneydisease AT hiroshikawada theeffectofroxadustatontransfusiondependentmyelodysplasticsyndromecomplicatedbychronickidneydisease AT kiyoshiando theeffectofroxadustatontransfusiondependentmyelodysplasticsyndromecomplicatedbychronickidneydisease AT ryujirohara effectofroxadustatontransfusiondependentmyelodysplasticsyndromecomplicatedbychronickidneydisease AT naokigoto effectofroxadustatontransfusiondependentmyelodysplasticsyndromecomplicatedbychronickidneydisease AT daisukefuruya effectofroxadustatontransfusiondependentmyelodysplasticsyndromecomplicatedbychronickidneydisease AT toshihikokitahara effectofroxadustatontransfusiondependentmyelodysplasticsyndromecomplicatedbychronickidneydisease AT hirokinumata effectofroxadustatontransfusiondependentmyelodysplasticsyndromecomplicatedbychronickidneydisease AT shigekiwatanabe effectofroxadustatontransfusiondependentmyelodysplasticsyndromecomplicatedbychronickidneydisease AT hiroshikawada effectofroxadustatontransfusiondependentmyelodysplasticsyndromecomplicatedbychronickidneydisease AT kiyoshiando effectofroxadustatontransfusiondependentmyelodysplasticsyndromecomplicatedbychronickidneydisease
_version_	1718393766302187520

The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease

Ejemplares similares